UK-based private equity firm Novalpina Capital has acquired a majority stake in Laboratoire XO, a French pharmaceutical company focused on the production and distribution of prescription drugs treating chronic diseases.
UK-based private equity firm Novalpina Capital has acquired a majority stake in Laboratoire XO, a French pharmaceutical company focused on the production and distribution of prescription drugs treating chronic diseases.
Recent Comments